Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole Oral Solution in Children and Adolescents With Autistic Disorder
NCT03487770Phase 3Completed
- Sponsor
- Otsuka Holdings
- Start
- Apr 2018
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of aripiprazole in Autism Spectrum Disorder (ASD), sponsored by Otsuka Holdings. Started Apr 2018; status: completed.
02
Drugs
aripiprazole
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT03487770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03487770.